Long-term outcomes of salvage high-dose-rate brachytherapy for localized recurrence of prostate cancer following definitive radiation therapy: a retrospective analysis
Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient popul...
Saved in:
| Published in | BMC cancer Vol. 25; no. 1; pp. 524 - 11 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
22.03.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population.
We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events.
Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy.
Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. |
|---|---|
| AbstractList | Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population.
We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events.
Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy.
Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. Abstract Background Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population. Methods We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan–Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events. Results Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1–169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy. Conclusions Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population. We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events. Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy. Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. Background Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population. Methods We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events. Results Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy. Conclusions Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. Keywords: Prostate cancer, Radiation therapy, High, Dose, Rate brachytherapy, Salvage therapy, Biochemical recurrence, Local recurrence, Androgen deprivation therapy, Long, Term outcomes, Toxicity, Cause, Specific survival Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population.BACKGROUNDSalvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population.We conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events.METHODSWe conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan-Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events.Thirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy.RESULTSThirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1-169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy.Salvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings.CONCLUSIONSSalvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. BackgroundSalvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This study aimed to evaluate the long-term safety and efficacy of HDR-BT alone, without androgen deprivation therapy (ADT), in this patient population.MethodsWe conducted a retrospective analysis of patients with prostate cancer who developed pathologically confirmed local recurrence after definitive radiation therapy and were treated with salvage HDR-BT alone at Kawasaki Medical School Hospital between 2007 and 2021. The prescribed HDR-BT dose was 22 Gy in 2 fractions. Biochemical relapse-free survival (bRFS), cause-specific survival (CSS), and overall survival (OS) were assessed using the Kaplan–Meier method. Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events.ResultsThirty-five patients were included, with a median follow-up of 66.0 months (range, 8.1–169.1). The 5-year bRFS, CSS, and OS rates were 29.7%, 100%, and 89.3%, respectively. Biochemical recurrence occurred in 21 patients (60.0%). Grade 2 adverse events were reported in eight patients (22.9%), while two (5.7%) experienced grade 3 adverse events. All grade 3 adverse events occurred in patients who had HDR-BT as their initial definitive radiation therapy.ConclusionsSalvage HDR-BT without ADT is a safe and effective treatment option for localized prostate cancer recurrence after definitive radiation therapy. It provides excellent CSS rates with acceptable toxicity while potentially reducing the need for ADT. Further prospective studies are warranted to confirm these findings. |
| ArticleNumber | 524 |
| Audience | Academic |
| Author | Kamitani, Nobuhiko Kawata, Yujiro Tamada, Tsutomu Miyaji, Yoshiyuki Watanabe, Kenta Katsui, Kuniaki Ikeda, Naoki Tokiya, Ryoji Hayashi, Takafumi |
| Author_xml | – sequence: 1 givenname: Kenta surname: Watanabe fullname: Watanabe, Kenta – sequence: 2 givenname: Nobuhiko surname: Kamitani fullname: Kamitani, Nobuhiko – sequence: 3 givenname: Naoki surname: Ikeda fullname: Ikeda, Naoki – sequence: 4 givenname: Yujiro surname: Kawata fullname: Kawata, Yujiro – sequence: 5 givenname: Ryoji surname: Tokiya fullname: Tokiya, Ryoji – sequence: 6 givenname: Takafumi surname: Hayashi fullname: Hayashi, Takafumi – sequence: 7 givenname: Yoshiyuki surname: Miyaji fullname: Miyaji, Yoshiyuki – sequence: 8 givenname: Tsutomu surname: Tamada fullname: Tamada, Tsutomu – sequence: 9 givenname: Kuniaki surname: Katsui fullname: Katsui, Kuniaki |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40121422$$D View this record in MEDLINE/PubMed |
| BookMark | eNptk1uL1DAUx4usuBf9Aj5IQRB96JpLL6kvsixeBgYEL8_hTHrSZsk0Y5Kujl_Ir2k6My47In1oOf2dX-jp_5xnJ6MbMcueUnJJqahfB8qEqArCqoLyloqCPcjOaNnQgpWkObn3fJqdh3BDCG0EEY-y05JQRkvGzrLfSzf2RUS_zt0UlVtjyJ3OA9hb6DEfTD8UnQtYeIiYrzyoYRsH9LDZ5tr53DoF1vzCLveoJu9xVDgLNt6FOLcoSBWfWGvdDzP2eYfajCaaW8w9dAaicWN-UL7JIXli6t2g2iEwgt0GEx5nDzXYgE8O94vs2_t3X68_FstPHxbXV8tCVZTEgvOWVSDKrl01wCjqFTLREN1pXa80F0LUWFeNLlVTdYwwjl3DkQpdE-B1y_lFtth7Owc3cuPNGvxWOjByV3C-l-CjURYl0lVNOWkaRXSJNYpSd0jLlrV1qmCbXG_3rs20WmOncIwe7JH0-M1oBtm7W0lpy9PPosnw8mDw7vuEIcq1CQqthRHdFCSngtSiZuV82PN_0Bs3-TS9HdVUpWh3wgPVQ_oCM2qXDlazVF4JPmdCsDpRl_-h0tXh2qgUQm1S_ajh1VFDYiL-jD1MIcjFl8_H7It77IBg4xCcneYchGPw2f3x3c3tb3gTwPaASoEJHvUdQomcN0TuN0SmDZG7DZGM_wEpaQQR |
| Cites_doi | 10.6004/jnccn.2012.0115 10.1016/s0360-3016(03)00632-1 10.1016/j.brachy.2013.11.005 10.3322/caac.21834 10.1007/s10147-024-02517-z 10.1053/srao.2003.50015 10.1016/j.urolonc.2013.12.014 10.1016/j.ijrobp.2013.01.027 10.1016/j.ejca.2015.07.019 10.1200/JCO.23.01391 10.1111/j.1464-410X.2012.11774.x 10.1038/s41391-018-0106-1 10.1016/j.radonc.2016.04.032 10.1002/cncr.20093 10.1016/j.euo.2018.12.011 10.1007/s11604-024-01621-4 10.3389/fonc.2022.971344 10.1007/s00066-017-1157-2 10.1111/iju.12373 10.1016/j.ijrobp.2006.04.029 10.1002/cncr.22940 10.1016/j.euo.2023.01.009 10.1016/j.prro.2021.04.007 10.1111/iju.14880 10.1001/jama.2013.8638 10.6004/jnccn.2022.0063 10.1016/j.ijrobp.2021.10.138 10.1002/cncr.26631 10.1111/j.1464-410X.2007.07045.x 10.1016/j.ijrobp.2018.06.039 10.1016/j.radonc.2019.09.006 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-025-13918-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_e1b613077c0f4e6e84fde149296c0fe9 PMC11930011 A832142826 40121422 10_1186_s12885_025_13918_2 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c510t-33925a84d9b7a21efbe2870fdff6bf38886e657f4c75d2023ed73e18f60a36933 |
| IEDL.DBID | DOA |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 00:49:49 EDT 2025 Thu Aug 21 18:40:07 EDT 2025 Fri Jul 11 07:58:55 EDT 2025 Fri Jul 25 21:01:51 EDT 2025 Tue Jun 17 21:58:30 EDT 2025 Tue Jun 10 20:59:51 EDT 2025 Fri Jun 27 05:12:55 EDT 2025 Thu May 22 21:23:30 EDT 2025 Fri May 16 02:46:38 EDT 2025 Tue Aug 05 12:08:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | High Androgen deprivation therapy Toxicity Local recurrence Term outcomes Radiation therapy Biochemical recurrence Salvage therapy Rate brachytherapy Specific survival Cause Long Dose Prostate cancer |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-33925a84d9b7a21efbe2870fdff6bf38886e657f4c75d2023ed73e18f60a36933 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/e1b613077c0f4e6e84fde149296c0fe9 |
| PMID | 40121422 |
| PQID | 3187548911 |
| PQPubID | 44074 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e1b613077c0f4e6e84fde149296c0fe9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11930011 proquest_miscellaneous_3180686249 proquest_journals_3187548911 gale_infotracmisc_A832142826 gale_infotracacademiconefile_A832142826 gale_incontextgauss_ISR_A832142826 gale_healthsolutions_A832142826 pubmed_primary_40121422 crossref_primary_10_1186_s12885_025_13918_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-22 |
| PublicationDateYYYYMMDD | 2025-03-22 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | JL Mohler (13918_CR8) 2019; 22 M Gaztañaga (13918_CR26) 2012; 10 F Bray (13918_CR1) 2024; 74 Y Yamada (13918_CR12) 2014; 13 G Ingrosso (13918_CR9) 2020; 3 N Kamitani (13918_CR27) 2022; 29 RF Wolff (13918_CR28) 2015; 51 DA Kuban (13918_CR3) 2003; 57 C Ménard (13918_CR31) 2022; 12 H Tran (13918_CR23) 2014; 32 H Ahmadi (13918_CR24) 2013; 111 SY Wu (13918_CR14) 2021; 11 J Crook (13918_CR19) 2022; 112 J Murgic (13918_CR16) 2018; 102 H Uddin Ahmed (13918_CR22) 2012; 118 CP Chen (13918_CR29) 2013; 86 D Khuntia (13918_CR4) 2004; 100 13918_CR30 D Pasquier (13918_CR10) 2023; 6 M Ismail (13918_CR21) 2007; 100 DC Beyer (13918_CR5) 2003; 13 G Chatzikonstantinou (13918_CR15) 2017; 193 13918_CR7 H Sasaki (13918_CR20) 2014; 21 P Wojcieszek (13918_CR13) 2016; 119 M Roach 3rd (13918_CR6) 2006; 65 I Henríquez López (13918_CR17) 2019; 141 C Ekanger (13918_CR11) 2024; 42 GW Allen (13918_CR18) 2007; 110 K Nakamura (13918_CR2) 2024; 29 F Lapi (13918_CR25) 2013; 310 N Kamitani (13918_CR32) 2024; 42 |
| References_xml | – volume: 10 start-page: 1088 year: 2012 ident: 13918_CR26 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2012.0115 – volume: 57 start-page: 915 year: 2003 ident: 13918_CR3 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/s0360-3016(03)00632-1 – volume: 13 start-page: 111 year: 2014 ident: 13918_CR12 publication-title: Brachytherapy doi: 10.1016/j.brachy.2013.11.005 – volume: 74 start-page: 229 year: 2024 ident: 13918_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21834 – volume: 29 start-page: 847 year: 2024 ident: 13918_CR2 publication-title: Int J Clin Oncol doi: 10.1007/s10147-024-02517-z – volume: 13 start-page: 158 year: 2003 ident: 13918_CR5 publication-title: Semin Radiat Oncol doi: 10.1053/srao.2003.50015 – ident: 13918_CR30 – volume: 32 start-page: 701 year: 2014 ident: 13918_CR23 publication-title: Urol Oncol doi: 10.1016/j.urolonc.2013.12.014 – volume: 86 start-page: 324 year: 2013 ident: 13918_CR29 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.01.027 – volume: 51 start-page: 2345 year: 2015 ident: 13918_CR28 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.07.019 – volume: 42 start-page: 1934 year: 2024 ident: 13918_CR11 publication-title: J Clin Oncol. doi: 10.1200/JCO.23.01391 – volume: 111 start-page: 543 year: 2013 ident: 13918_CR24 publication-title: BJU Int doi: 10.1111/j.1464-410X.2012.11774.x – volume: 22 start-page: 309 year: 2019 ident: 13918_CR8 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/s41391-018-0106-1 – volume: 119 start-page: 405 year: 2016 ident: 13918_CR13 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2016.04.032 – volume: 100 start-page: 1283 year: 2004 ident: 13918_CR4 publication-title: Cancer doi: 10.1002/cncr.20093 – volume: 3 start-page: 183 year: 2020 ident: 13918_CR9 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2018.12.011 – volume: 42 start-page: 1322 year: 2024 ident: 13918_CR32 publication-title: Jpn J Radiol doi: 10.1007/s11604-024-01621-4 – volume: 12 year: 2022 ident: 13918_CR31 publication-title: Front Oncol doi: 10.3389/fonc.2022.971344 – volume: 193 start-page: 683 year: 2017 ident: 13918_CR15 publication-title: Strahlenther Onkol doi: 10.1007/s00066-017-1157-2 – volume: 21 start-page: 572 year: 2014 ident: 13918_CR20 publication-title: Int J Urol doi: 10.1111/iju.12373 – volume: 65 start-page: 965 year: 2006 ident: 13918_CR6 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.04.029 – volume: 110 start-page: 1405 year: 2007 ident: 13918_CR18 publication-title: Cancer doi: 10.1002/cncr.22940 – volume: 6 start-page: 399 year: 2023 ident: 13918_CR10 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2023.01.009 – volume: 11 start-page: 515 year: 2021 ident: 13918_CR14 publication-title: Pract Radiat Oncol doi: 10.1016/j.prro.2021.04.007 – volume: 29 start-page: 725 year: 2022 ident: 13918_CR27 publication-title: Int J Urol doi: 10.1111/iju.14880 – volume: 310 start-page: 289 year: 2013 ident: 13918_CR25 publication-title: JAMA doi: 10.1001/jama.2013.8638 – ident: 13918_CR7 doi: 10.6004/jnccn.2022.0063 – volume: 112 start-page: 1115 year: 2022 ident: 13918_CR19 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2021.10.138 – volume: 118 start-page: 3071 year: 2012 ident: 13918_CR22 publication-title: Cancer doi: 10.1002/cncr.26631 – volume: 100 start-page: 760 year: 2007 ident: 13918_CR21 publication-title: BJU Int doi: 10.1111/j.1464-410X.2007.07045.x – volume: 102 start-page: 561 year: 2018 ident: 13918_CR16 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2018.06.039 – volume: 141 start-page: 156 year: 2019 ident: 13918_CR17 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2019.09.006 |
| SSID | ssj0017808 |
| Score | 2.437668 |
| Snippet | Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation therapy. This... Background Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation... BackgroundSalvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive radiation... Abstract Background Salvage high-dose-rate brachytherapy (HDR-BT) is a potential treatment for localized recurrence of prostate cancer following definitive... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 524 |
| SubjectTerms | Adverse events Aged Aged, 80 and over Analysis Antigens Biopsy Brachytherapy Brachytherapy - adverse effects Brachytherapy - methods Cancer Cancer therapies Care and treatment CT imaging Development and progression Disease control Dose Dosimetry Follow-Up Studies High Humans Magnetic resonance imaging Male Metastasis Middle Aged Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - radiotherapy Patient outcomes Patients Planning Prostate cancer Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Radiation therapy Radioisotope brachytherapy Radiotherapy Radiotherapy Dosage Rate brachytherapy Regression analysis Relapse Retrospective Studies Salvage therapy Salvage Therapy - adverse effects Salvage Therapy - methods Scintigraphy Survival Tomography Toxicity Treatment Outcome Ultrasonic imaging X-rays |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgift_qqVEEH6Rc27RJ1hc5xeMUzwf1YN9Cmo-9haVZ213l_If8N51Js-sVwddmGtrMR2aSmd8Q8kIYk8sK9Ns3BcNrRpc13pqsNqKxNauNjecdp5_5yVn1cVbP0oFbn9IqtzYxGmobDJ6RH4LsCfCuQTffrL5n2DUKb1dTC42r5BpCl2FKl5jtAq5CyFxuC2UkP-zBFkusR64z8HsKkJDRZhQx-_-1zJe2pnHa5KV96PgWuZkcSHo0cPw2ueLaO-T6aboiv0t-fwrtPEODS8NmDf_meho87fXyB5gOivDEmQ29yxAjgkKsbM4vhiKsCwoOLI2b2-KXs7TDo_hYDIgTrLA8BF8xKCcd0C6X4SdsfNQ6vxhSkGiHSAfIapqmfE01zLPuwraik-qEgnKPnB2___buJEvdGDIDervOGHhStZaVnTZCl4XzjcNLUm-9541nEElzx2vhKyNqi03ZnRXMFdLzXDM-Zew-2WtD6_YJ1daDG-EMdrmvpPaN1BWDwK0GcwPbpZ2QV1u2qNUAuqFisCK5GpiogIkqMlGVE_IWObejRMDs-CB0c5X0T7miwUhJCJP7ynEnK28dRIfllMMTN52Qp8h3NVSf7tReHcVOThCX8gl5HikQNKPFrJy53vS9-vD1y4joZSLyAWTE6FTkAP-NOFsjyoMRJWi1GQ9vBVAlq9KrvzowIc92w_gmZsq1LmwizVD1A7_0YJDX3cpUCOBXlbBiciTJo6Ubj7SL84g5DurFMHx4-P_vekRulKhfOcvK8oDsrbuNewxe27p5ElXzD4YGREQ priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZKkRAXxJvQAgYhcUCBPBzbi4RQQVQFsRyAlXqzHD-2K62SNtkFlj_E32TGSZZG9Mg1Hluy5x17viHkqTAmkQz025dpjteMLi69NXFhRGmLvDA2_O-YfuZHM_bxuDjeIUO7o_4A2wtTO-wnNWuWL36ebd6Awr8OCi_5yxZsrMQ64yKGeCYFzl8il8EzCVTUKft7qyBkIofCmQvnjZxTwPD_11Kfc1XjZ5Tn_NLhdXKtDyjpQScBN8iOq26SK9P-yvwW-f2pruYxGmBar1cgX66ltaetXn4HU0IRrji2detixIygkDubk01XlLWhENDS4OwWv5ylDf6aD8WBuMAplovgFINy0wDtcln_AEdIrfOL7kkSbRD5AFlP-yVfUQ3rrJp6qPCkukdFuU1mh--_vTuK--4MsQE9XsU5RFaFlsxOSqGz1PnS4aWpt97z0ueQWXPHC-GZEYXFJu3Oityl0vNE53yS53fIblVX7h6h2noIK5zBrvdMal9KzXJI5AowP-A-bUSeD2xRpx0IhwrJi-SqY6ICJqrARJVF5C1ybkuJANrhQ93MVa-PyqUlZk5CmMQzx51k3jrIFrMJhy9uEpFHyHfVVaNuzYA6CJ2dIE_lEXkSKBBEo8JXOnO9blv14euXEdGznsjXICNG90UPsG_E3RpR7o8oQcvNeHgQQDUoiQJ7LCDjBH8VkcfbYZyJL-cqV68DTVcFBFu628nr9mQYAvqxDE5MjiR5dHTjkWpxEjDIUwj8MZ24_z8Oe49czVALkzzOsn2yu2rW7gHEeqvyYVDgP1lmVIU priority: 102 providerName: Scholars Portal |
| Title | Long-term outcomes of salvage high-dose-rate brachytherapy for localized recurrence of prostate cancer following definitive radiation therapy: a retrospective analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40121422 https://www.proquest.com/docview/3187548911 https://www.proquest.com/docview/3180686249 https://pubmed.ncbi.nlm.nih.gov/PMC11930011 https://doaj.org/article/e1b613077c0f4e6e84fde149296c0fe9 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgLKu-lZTEIiQOKmodje7l1UauC2AotVFpxsRw_2pVWSZXsgsof4m8y4ySrjThw4ZJDPLGSeU_s-UzIG2FMLBnYty-SDJcZXVR4a6LciMLmWW5s-N8xO-dnF-zTIl_sHPWFe8JaeOCWcUcuKTDFFcLEnjnuJPPWQVqfTjjccaF1D2JeX0x16wdCxrJvkZH8qAEvLLETOY8g40lANwZhKKD1_-2Td4LScMPkTgQ63Sf3u9SRHrev_IDccuVDcnfWLY4_Ir8_V-VlhK6WVps1aJJraOVpo1c_wGlQBCaObNW4CNEhKFTJ5uqmbb-6oZC60hDWlr-cpTX-hA9tgDjBNTaG4CMGNaQG2tWq-gkhj1rnl-3mI1ojxgEKmXZTvqca5lnXVd_LSXWHf_KYXJyefPtwFnXnMEQGLHYdZZBD5VoyOymEThPnC4fLo956zwufQQ3NHc-FZ0bkFo9jd1ZkLpGexzrjkyx7QvbKqnTPCNXWQwLhDJ5vz6T2hdQsg5ItB0cDgdKOyLteLOq6hdtQoUyRXLVCVCBEFYSo0hGZouS2lAiVHW6AAqlOgdS_FGhEXqLcVdt3ujV4dRzOcIKKlI_I60CBcBkl7se51JumUR-_zgdEbzsiX4GOGN21N8B3I8LWgPJwQAn2bIbDvQKqzp80CjyvgNoSItOIvNoO45O4R6501SbQtP0-8ElPW33dcoYhdB9LgWNyoMkD1g1HyuVVQBtPIMXHwuH5_2D2AbmXohXGWZSmh2RvXW_cC8jq1sWY3BYLMSZ3pifnX-bjYM5wnTEJ1_n0-x9_FlFR |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcKgxkE4gFFa26Oi4TQBpta1lZobNLeTOJLV6mKS9IylT_EG7-Rc5ykLELiba_xiZX4XD_b5xxCXiVS9ngE-m0yP8RjRu1lRkkvlkmm4jCWyu13jCdscBZ9Po_Pt8jvJhcGr1U2NtEZamUl7pHvgewlEF2Dbn5YfPewaxSerjYtNCqxONbrS4Bs5fvhJ-Dv6yA4Ojz9OPDqrgKeBPlbeiFEBHHKI9XPkjTwtck0HvYZZQzLTAiIkGkWJyaSSaywubhWSah9blgvDVkfN0DB5G9HIUCZDtk-OJx8OdmcWyS8x5vUHM72SrD-HDOgYw8iLR9ksuX-XJeAf33BFWfYvqh5xfMd3SG365CV7lcydpds6fweuTGuD-Xvk18jm089NPHUrpawmrqk1tAynf8AY0WxILKnbKk9rEpBAZ3Li3WV9rWmEDJT505nP7WiBW7-u_RDnGCBCSn4ikTJLIB2PreX4Gqp0mZWXXqiBdZWQOGi9ZTvaArzLAvb5JDStK678oCcXQunHpJObnP9mNBUGQhctPQBfEc8NRlPoxCgYgwGDhy06pK3DVvEoirzIRw84kxUTBTAROGYKIIuOUDObSixRLd7YIupqDVeaD9DbJYksmcizTSPjNKAR4M-gye63yW7yHdR5btuDI3Yd72jAAmzLnnpKLBMR473gKbpqizF8OtJi-hNTWQsyIhM67QK-G-s7NWi3GlRgh2R7eFGAEVtx0rxV-u65MVmGN_Eu3m5titHU-UZwS89quR1szIRlgyMAlgx3pLk1tK1R_LZhaty7gO0QMDy5P_ftUtuDk7HIzEaTo6fklsB6lov9IJgh3SWxUo_g5hxmT2vFZWSb9dtG_4AFm2CGQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+outcomes+of+salvage+high-dose-rate+brachytherapy+for+localized+recurrence+of+prostate+cancer+following+definitive+radiation+therapy%3A+a+retrospective+analysis&rft.jtitle=BMC+cancer&rft.au=Kenta+Watanabe&rft.au=Nobuhiko+Kamitani&rft.au=Naoki+Ikeda&rft.au=Yujiro+Kawata&rft.date=2025-03-22&rft.pub=BMC&rft.eissn=1471-2407&rft.volume=25&rft.issue=1&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1186%2Fs12885-025-13918-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e1b613077c0f4e6e84fde149296c0fe9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |